Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Cognitive and Hand Functions in SPMS
NCT06599307Phase 2Recruiting
- Sponsor
- Cairo University
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in secondary-progressive multiple sclerosis (SPMS), sponsored by Cairo University. Started Aug 2024; status: recruiting.
02
Drugs
rituximab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT06599307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599307.